IEQ Capital
JBIO icon

IEQ Capital’s Jade Biosciences JBIO Stock Holding History

IEQ Capital’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-448
Closed -$39.3K – 1825
2025
Q1 		$39.3K Buy
448
+37
+9% +$3.25K ﹤0.01% 1562
2024
Q4 		$38.1K Buy
+411
New +$35.4K ﹤0.01% 1305

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

IEQ Capital's JBIO Position: Q2 2025 in Review

IEQ Capital sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 448 shares — an estimated $39.3K sold.

IEQ Capital first reported a position in JBIO in Q4 2024 and held it in 2 quarters. The position peaked at $39.3K in Q1 2025. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • IEQ Capital reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • IEQ Capital sold 448 Jade Biosciences shares in Q2 2025, an estimated $39.3K.
  • IEQ Capital first reported a position in Jade Biosciences in Q4 2024 and held it in 2 quarters.
  • IEQ Capital's Jade Biosciences position peaked at $39.3K in Q1 2025.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on IEQ Capital's 13F filing for Q2 2025, filed 14 Aug 2025.